definiens: means the program of research defined in Schedule 1 under the title CAT19 Program asconducted prior to the Second Amendment Date ; means excluding Manufacturing Know - How, ( i ) those patent applications listed inSchedule 2 under the title CAT19 Patents and all Patent Rights derived therefrom ( ) ; ( ii ) the Know - How described in Schedule 2 under the title CAT19 Know - How, including CARPALL andALLCAR19 Patient Clinical Data generated prior to the Second Amendment Date once the same is disclosedto [COMPANY] in accordance with Clause 9.8 ; ( iii ) the materials listed in Schedule 2 under the title CAT19 Materialstogether with all IP in the same ; and ( iv ) any Know - How generated in the performance of the ALLCAR19 andCARPALL Studies after the Second Amendment Date, which shall include CARPALL and ALLCAR19 PatientClinical Data once disclosed to [COMPANY] in accordance with Clause 9.8, but excluding any such Know - How inwhich [COMPANY] has rights pursuant to any agreement entered into in accordance with Clause 4.12 and excludingany Know - How owned by [ * * * ] pursuant to the [ * * * ] Agreements ; means a chimeric antigen receptor ( also known as chimeric immunoreceptors or artificial T - Cellreceptors ) comprising an extra - cellular Antigen binding or recognition domain and one or more intra - cellularsignalling domains, wherein the extra - cellular Antigen binding or recognition domain has binding specificity forone particular Antigen, and for the avoidance of doubt is not a BiTE ; has the meaning set out in Clause 2.2.7 ; means any product or therapy which, were it not for the licence to ccCAR Patent Rightsgranted hereunder, would otherwise infringe the ccCAR Patent Rights in the relevant country of sale ; means the program of research defined in Schedule 1 under the title ccCAR Program asconducted prior to the Amendment Date ; means excluding Manufacturing Know - How, ( i ) those patent applications listed inSchedule 2 under the title ccCAR Patents and all Patent Rights derived therefrom ( ) ; ( ii)the Know - How described in Schedule 2 under the title ccCAR Know - How ; and ( iii ) the materials listed inSchedule 2 under the title ccCAR Materials together with all IP in the same ; CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT . THE COPY FILEDHEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST . OMISSIONS AREDESIGNATED [ * * * ] . A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THESECURITIES AND EXCHANGE COMMISSION